As more SMA treatments become available, people living with SMA, their families, and caregivers are asking new questions about how treatments work, whether using more than one treatment could help, and what to consider when thinking about combination therapy. Understanding how SMA treatments work can help individuals and families feel more informed about their options and better prepared for conversations with their SMA healthcare team.
Cure SMA is committed to providing the SMA community with resources to support learning and decision-making. To assist with that goal, we are pleased to share two new resources: an updated Care Series booklet: Understanding Combination Therapy, and a new video explaining muscle-directed therapy: Understanding Muscle-Targeted Anti-Myostatin Therapy for Spinal Muscular Atrophy (SMA).
In SMA, combination therapy means using two or more treatments at the same time or in sequence, whether they work in similar or different ways. Combination therapy is being explored because SMA affects more than one part of the body, and no single treatment works the same way for every person. Research is asking whether treatments that work in different ways — at the gene, the nerve, and the muscle — could be used together to help meet the different needs of each person living with SMA.
About the Booklet
Understanding Combination Therapy: A Plain-Language Guide for People Living with SMA, Families, and Caregivers explains how current SMA treatments work, why combination therapy is being discussed, what recent research shows, what to know about insurance coverage and access, and what questions to bring to your SMA healthcare team. It is meant to support informed conversations, not to recommend a specific treatment plan. The booklet is available here.
About the Video
The video focuses on muscle-targeted therapy, a newer approach to treating SMA. While SMN-targeted treatments work by increasing levels of SMN protein in the body, muscle-targeted therapies work at the level of the muscle itself. The video introduces myostatin — a protein that acts as a biological brake on muscle growth — and explains how blocking myostatin may help address muscle weakness that can persist even after SMN-targeted treatment. You can watch the video here.
As always, treatment decisions should be made in conversation with your SMA healthcare team, based on what is best for you and your family.
Both resources were developed by Cure SMA with support from Scholar Rock.
